Oracle Press Release

Oracle Health Sciences Institute, in Partnership with Oracle Labs, Announces First Round of Research Projects

Initiatives will Focus on Advancing IT Innovation to Support Personalized Medicine and the Development and Delivery of Effective Treatments

Redwood Shores, Calif. – Jan. 31, 2012

News Facts

Oracle Health Sciences Institute, in partnership with Oracle Labs, today announced its first group of research projects, which includes initiatives with Brigham and Women’s Hospital and Harvard Medical School; the Coalition Against Major Diseases (CAMD) at the Critical Path Institute; the Human-Computer Interaction Lab (HCIL) at the University of Maryland.
The Brigham and Women’s Hospital and Harvard Medical School research team will create an IT framework that helps to extract, manage and analyze relevant data from electronic medical records and medical claims to enable causal inference and improve comparison of the effectiveness of various treatments. The team will also work to develop a repeatable approach that allows organizations to use the framework to better understand the relationships between prescription drug use and health outcomes.
The Coalition Against Major Diseases (CAMD) at Critical Path Institute (C-Path) will explore the use of Oracle Health Sciences Empirica Study On Demand to perform data mining and analysis on C-Path’s Online Data Repository. This database contains clinical data for over 5,700 patients with Alzheimer’s disease, pooled from the control arms of twenty pharmaceutical and other clinical trials.  Working with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), researchers hope to learn how to effectively apply advanced data mining methods and tools to gain insight that is helpful in the evaluation of efficacy and safety of new treatments for neurodegenerative diseases.
The Human-Computer Interaction Lab at the University of Maryland will expand development of a tool to facilitate the visualization of patient clinical data patterns over time, as they apply to drug safety signals in large repositories of longitudinal healthcare and claims data. Visual data has been proven to significantly improve the thought processes of researchers. As such, the newly-designed tool is expected to help accelerate and broaden adverse events analysis, leading to new insights, as well as expanded research opportunities.
Oracle Health Sciences Institute, in partnership with Oracle Labs, focuses on supporting research that accelerates IT innovation to advance personalized medicine and the delivery of safe and effective treatments and healthcare services to patients around the globe.

Supporting Quote

“IT innovation fuels the transformation needed to realize the full potential of the convergence of healthcare and life sciences,” said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences. “Oracle Health Sciences Institute, in partnership with Oracle Labs, is committed to expanding the horizons of health IT innovation. We are pleased to support esteemed research project teams as they seek new ways to apply information technology to advance the discovery and development of next-generation treatments and therapies.”

Supporting Resources

About Oracle

Oracle engineers hardware and software to work together in the cloud and in your data center.  For more information about Oracle (NASDAQ:ORCL), visit www.oracle.com.

Trademark

Oracle is a registered trademark of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.

# # #

Contact Info

Greg Lunsford
Oracle
+1.650.506.6523
greg.lunsford@oracle.com

Mary Tobin
O’Keeffe & Company
+1.503.658.7396
mtobin@okco.com